Merrion
Friday, 07 November 2008Advised Merrion on their license agreement with Novo Nordisk to develop and commercialise oral formulations of Novo Nordisk’s proprietary Insulin analogues, using Merrion’s proprietary GIPET® technology.
Advised Merrion on their license agreement with Novo Nordisk to develop and commercialise oral formulations of Novo Nordisk’s proprietary Insulin analogues, using Merrion’s proprietary GIPET® technology.